[go: up one dir, main page]

MX2010005530A - Activadores de receptor de vitamina d nuevos y metodos de elaboracion de los mismos. - Google Patents

Activadores de receptor de vitamina d nuevos y metodos de elaboracion de los mismos.

Info

Publication number
MX2010005530A
MX2010005530A MX2010005530A MX2010005530A MX2010005530A MX 2010005530 A MX2010005530 A MX 2010005530A MX 2010005530 A MX2010005530 A MX 2010005530A MX 2010005530 A MX2010005530 A MX 2010005530A MX 2010005530 A MX2010005530 A MX 2010005530A
Authority
MX
Mexico
Prior art keywords
methods
making
receptor activators
new vitamin
compounds
Prior art date
Application number
MX2010005530A
Other languages
English (en)
Inventor
David M Barnes
Jinshyun Ruth Wu-Wong
Xiaofeng Li
John E Hengeveld
Thomas W Von Geldern
Jufang H Burkalow
Anghony R Haight
Maureen A Mclaughlin
William T Noonan
Zhonghua Pei
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2010005530A publication Critical patent/MX2010005530A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C27/00—Processes involving the simultaneous production of more than one class of oxygen-containing compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos que son activadores del receptor de vitamina D, composiciones que comprenden dichos compuestos, métodos para usar dichos compuestos y composiciones, procesos para preparar dichos compuestos e intermediarios obtenidos durante dichos procesos.
MX2010005530A 2007-11-20 2008-11-20 Activadores de receptor de vitamina d nuevos y metodos de elaboracion de los mismos. MX2010005530A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98916707P 2007-11-20 2007-11-20
US12/205,998 US8377913B2 (en) 2007-11-20 2008-09-08 Vitamin D receptor activators and methods of making
PCT/US2008/084142 WO2009067578A2 (en) 2007-11-20 2008-11-20 New vitamin d receptor activators and methods of making

Publications (1)

Publication Number Publication Date
MX2010005530A true MX2010005530A (es) 2010-06-02

Family

ID=40642621

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005530A MX2010005530A (es) 2007-11-20 2008-11-20 Activadores de receptor de vitamina d nuevos y metodos de elaboracion de los mismos.

Country Status (14)

Country Link
US (1) US8377913B2 (es)
EP (1) EP2222635A2 (es)
JP (1) JP5544298B2 (es)
KR (1) KR101643199B1 (es)
CN (2) CN101918358B (es)
AU (1) AU2008326359A1 (es)
BR (1) BRPI0820043A8 (es)
CA (1) CA2705987A1 (es)
IL (1) IL205764A (es)
MX (1) MX2010005530A (es)
RU (1) RU2535448C2 (es)
TW (1) TWI483728B (es)
WO (1) WO2009067578A2 (es)
ZA (1) ZA201003324B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010236642B2 (en) * 2009-04-17 2014-06-26 Vidasym, Inc. Vitamin D receptor agonists and uses thereof
JP5770261B2 (ja) * 2010-03-23 2015-08-26 ウイスコンシン アラムニ リサーチ ファンデーション （２０Ｓ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ジヒドロキシビタミンＤ３および（２０Ｒ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ヒドロキシビタミンＤ３
EP2556054B1 (en) * 2010-03-23 2017-09-27 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
WO2012174095A1 (en) * 2011-06-14 2012-12-20 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses
US8410080B1 (en) * 2011-10-21 2013-04-02 Wisconsin Alumni Research Foundation 2-methylene-vitamin D analogs and their uses
AU2016303346B2 (en) * 2015-08-05 2021-01-28 Wisconsin Alumni Research Foundation Synthesis and biological activity of 2-methylene analogs of calcitriol and related compounds
CN105732307B (zh) * 2016-01-28 2019-04-19 科贝源(北京)生物医药科技有限公司 马沙骨化醇中间体的合成方法
EP4233989B1 (en) 2017-06-07 2026-01-14 Supira Medical, Inc. Intravascular fluid movement devices, systems, and methods of use
CN111556763B (zh) 2017-11-13 2023-09-01 施菲姆德控股有限责任公司 血管内流体运动装置、系统
CN112004563B (zh) 2018-02-01 2024-08-06 施菲姆德控股有限责任公司 血管内血泵以及使用和制造方法
US12161857B2 (en) 2018-07-31 2024-12-10 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
EP3860675A4 (en) 2018-10-05 2022-07-13 Shifamed Holdings, LLC INTRAVASCULAR BLOOD PUMPS AND METHODS OF USE
EP3996797A4 (en) 2019-07-12 2023-08-02 Shifamed Holdings, LLC INTRAVASCULAR BLOOD PUMPS AND METHOD OF USE AND METHOD OF MAKING
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
EP4010046A4 (en) 2019-08-07 2023-08-30 Calomeni, Michael Catheter blood pumps and collapsible pump housings
WO2021062270A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible pump housings
US11724089B2 (en) 2019-09-25 2023-08-15 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof
WO2021062260A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible blood conduits
KR102472541B1 (ko) * 2019-11-27 2022-11-30 연성정밀화학(주) 막사칼시톨의 제조방법 및 그를 위한 중간체
EP4072650A4 (en) 2019-12-11 2024-01-10 Shifamed Holdings, LLC Descending aorta and vena cava blood pumps
WO2025058098A1 (ko) * 2023-09-12 2025-03-20 (주)수파드엘릭사 비타민 ｄ 수용체 활성화 펩타이드 및 이를 포함하는 화장료 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188345A (en) * 1978-07-26 1980-02-12 Wisconsin Alumni Research Foundation Fluorovitamin D compounds and processes for their preparation
JPS63208568A (ja) 1987-02-26 1988-08-30 Chugai Pharmaceut Co Ltd 新規なビタミンｄ誘導体
JPH02162A (ja) * 1987-06-23 1990-01-05 Yamanouchi Pharmaceut Co Ltd 新規なビタミンｄ↓３誘導体
AU629831B2 (en) 1988-04-29 1992-10-15 Wisconsin Alumni Research Foundation Side chain unsaturated 1 alpha-hydroxyvitamin d homologs for the treatment of leukemia
JPH0667898B2 (ja) 1989-02-15 1994-08-31 大同ほくさん株式会社 ２２，２３―セコビタミンｄ若しくはその活性型またはそれらの誘導体の製造方法
GB8904154D0 (en) * 1989-02-23 1989-04-05 Leo Pharm Prod Ltd Chemical compounds
NZ232734A (en) * 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
GB8914963D0 (en) * 1989-06-29 1989-08-23 Leo Pharm Prod Ltd Chemical compounds
GB9007236D0 (en) 1990-03-30 1990-05-30 Leo Pharm Prod Ltd Chemical compounds
AU650751B2 (en) * 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
GB9226860D0 (en) * 1992-12-23 1993-02-17 Leo Pharm Prod Ltd Novel treatment
PE28297A1 (es) * 1995-01-26 1997-08-20 Hoffmann La Roche Empleo dermatologico de derivados de vitamina d
US5614512A (en) * 1995-10-05 1997-03-25 Wisconsin Alumni Research Foundation 20-Oxo-pregnacalciferol analogs with binding affinity to the progesterone receptor
GB9611603D0 (en) * 1996-06-04 1996-08-07 Leo Pharm Prod Ltd Chemical compounds
KR100494205B1 (ko) * 1996-06-04 2005-11-08 레오 파마 에이/에스 신규한비타민d동족체
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
KR20010012770A (ko) 1997-05-22 2001-02-26 세파론, 인코포레이티드 비타민 ｄ 유사체 및 그 뉴런 효과
JP2001089442A (ja) * 1999-09-20 2001-04-03 Nisshin Flour Milling Co Ltd 活性型ビタミンｄ誘導体
RU2253455C2 (ru) 2000-01-31 2005-06-10 Лео Фарма А/С Применение производных витаминов d в лечении остеопороза и связанных заболеваний костей, а также новых производных витамина d3
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
WO2006123726A1 (ja) * 2005-05-18 2006-11-23 Kyowa Hakko Kogyo Co., Ltd. 医薬組成物

Also Published As

Publication number Publication date
BRPI0820043A2 (pt) 2015-05-12
JP2011504180A (ja) 2011-02-03
IL205764A (en) 2014-12-31
IL205764A0 (en) 2010-11-30
CN101918358B (zh) 2015-10-14
JP5544298B2 (ja) 2014-07-09
KR101643199B1 (ko) 2016-07-27
TWI483728B (zh) 2015-05-11
EP2222635A2 (en) 2010-09-01
RU2010125131A (ru) 2011-12-27
US20090131379A1 (en) 2009-05-21
CN104211626A (zh) 2014-12-17
BRPI0820043A8 (pt) 2016-03-08
AU2008326359A1 (en) 2009-05-28
CN101918358A (zh) 2010-12-15
WO2009067578A3 (en) 2009-11-26
ZA201003324B (en) 2011-10-26
RU2535448C2 (ru) 2014-12-10
TW200934502A (en) 2009-08-16
WO2009067578A2 (en) 2009-05-28
US8377913B2 (en) 2013-02-19
KR20100099181A (ko) 2010-09-10
CA2705987A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
MX2010005530A (es) Activadores de receptor de vitamina d nuevos y metodos de elaboracion de los mismos.
MY148253A (en) Azaadamantane derivatives and methods of use
MX2010003599A (es) Intermediarios y metodos para la sintesis de analogos de halicondrina b.
MX2011001679A (es) Derivados de flavina.
MX2010008714A (es) Derivados de amida como moduladores alostericos positivos y metodos de uso de los mismos.
MX2010010407A (es) Derivados de 4-aminociclohexanos sustituidos.
MX2009009773A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2010003685A (es) Analogos de quinolona y metodos relacionados con los mismos.
MX2011011797A (es) Fenilureas y fenilamidas sustituidas como ligandos del receptor de vanilloides.
MX2009008660A (es) Metodo para la preparacion de derivados de trifenilbuteno terapeuticamente valiosos.
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MX2009006750A (es) Derivados de azaadamantano espirociclicos y metodos de uso.
WO2009053446A3 (en) Pregabalin intermediates and process for preparing them and pregabalin
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
WO2007132354A3 (en) Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof
PH12012501153A1 (en) Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
MX2011013790A (es) Derivados de flavina.
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
TW200825088A (en) Processes for preparing intermediates of pemetrexed

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE INC.

FG Grant or registration